statementSaid on 2026-11-11
LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
其LY03017針對阿爾茨海默病精神病性障礙已在中國進入Ⅱ期臨床並完成首例給藥,LY03020作為全球首個TAAR1/5-HT2CR雙靶點激動劑,同樣將阿爾茨海默病精神病性障礙列為目標適應症。